CABA
Cabaletta BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
If 1H26 data remain supportive across SLE, SSc and MG, and automated manufacturing plus no-preconditioning approaches look viable, Cabaletta could move from a single-program story toward a broader autoimmune platform with materially higher strategic value.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.8.
What can break
Cash runway only into Q4 2026 raises financing risk if timelines slip or data do not strengthen partnering leverage.
Momentum
9
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.60 · Bull $6.00 · Bear $1.60
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-16 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $13.38
Why
Momentum9 · Δ7d -4.0
Value41 · Δ7d -0.1
Sentiment73 · Δ7d -5.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
9
26% active weight
Current posture
7d trendSoftening
Δ7d
-4.0
Δ21d
-36.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.8
Δ21d
-2.7
Why this grade
Composite grade D. Momentum 9.4 / Value 41.1 / Sentiment 72.6
Fundamentals (TTM)As of 2026-07-16
Fundamentals (TTM)
As of 2026-07-16
Market Cap
$435.36M
Beta
3.26
Shares Out
163.06M
P/E (TTM) · Derived
-1.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.70
Rev YoY
-
EPS YoY
-45.2%
Gross Margin
-
Op Margin
-
Net Debt
-$106.5M
Current Ratio
2.95
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology